Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Iconovo

1.23 SEK

+2.94 %

Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+2.94 %
-32.88 %
-42.76 %
-19.41 %
-67.32 %
-71.76 %
-97.31 %
-97.24 %
-96.24 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Read more
Market cap
65M SEK
Turnover
58.87K SEK
Revenue
2.93M
EBIT %
-1,402.05 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15.12
2025

Extraordinary general meeting '25

27.2
2026

Annual report '25

All
Press releases
ShowingAll content types
Press release11/26/2025, 11:47 AM

DNB Carnegie Access: Iconovo: Raises capital

Iconovo
Regulatory press release11/25/2025, 8:05 PM

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments

Iconovo
Press release10/31/2025, 10:21 AM

DNB Carnegie Access: Iconovo: New interim CEO appointed

Iconovo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release10/31/2025, 8:35 AM

Iconovo appoints new CEO

Iconovo
Press release10/27/2025, 1:13 PM

Redeye: Iconovo (Q3 Review) - An uneventful quarter with solid cost-cutting

Iconovo
Press release10/27/2025, 8:00 AM

DNB Carnegie Access: Iconovo - Rapportintervju Q3(25)

Iconovo
Press release10/24/2025, 4:16 PM

DNB Carnegie Access: Iconovo: Costs down, focus sharpened – Q3 review

Iconovo
Regulatory press release10/24/2025, 6:30 AM

QUARTERLY REPORT Q3 2025

Iconovo
Press release10/14/2025, 2:26 PM

DNB Carnegie Access: Iconovo: Financial targets withdrawn

Iconovo
Regulatory press release10/14/2025, 1:37 PM

Iconovo reworks its strategic goals

Iconovo
Regulatory press release8/13/2025, 2:00 PM

Iconovo AB changes Certified Adviser to Tapper Partners AB

Iconovo
Press release7/15/2025, 8:37 AM

Redeye: Iconovo Q2 - An undramatic report with early signs of cost reductions

Iconovo
Press release7/15/2025, 5:30 AM

DNB Carnegie Access: Iconovo: Quiet Q2 but funded with a stronger ownership base

Iconovo
Regulatory press release7/14/2025, 6:30 AM

QUARTERLY REPORT Q2 2025

Iconovo
Regulatory press release6/11/2025, 2:45 PM

Iconovo’s rights issue is registered – conversion of BTA into shares

Iconovo
Press release6/11/2025, 6:30 AM

Iconovo’s development of intranasal GLP-1 for a more convenient treatment of obesity is making significant progress

Iconovo
Regulatory press release6/9/2025, 6:15 AM

Iconovo's nomination committee proposes the election of Christer Fåhraeus as new board member

Iconovo
Regulatory press release6/3/2025, 2:42 PM

Iconovo announces final outcome in the rights issue

Iconovo
Regulatory press release6/2/2025, 4:50 PM

Iconovo announces preliminary outcome of rights issue

Iconovo
Regulatory press release5/27/2025, 8:30 AM

Last day of trading in subscription rights in Iconovo

Iconovo
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.